Jeffrey L. Port

Based at Cornell University, Jeffrey L. Port focuses their scholarly efforts on lung cancer surgery, minimally invasive thoracic surgery, esophageal cancer treatment, sublobar resection, robotic-assisted surgery, neoadjuvant therapy, surgical outcomes, thoracic oncology, bridging the gap between theory and practice in lung cancer surgery. A representative example of their recent contribution is the study titled "Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial", which offers critical insights into the dynamics of lung cancer surgery and minimally invasive thoracic surgery. Additional work such as "Robotic One Anaesthetic Marking And Resection ( <scp>ROMAR</scp> ): A Novel Approach for Thoracoscopic Sublobar Resection of Peripheral Pulmonary Lesions" further demonstrates their commitment to advancing knowledge in this domain.